Innovative medicines to extend healthy lifespan.

We extend healthy lifespan through innovative medicines. Our approach centres around developing medicines that target core aging mechanisms to not only treat but prevent age-related diseases.

Explore Now

Pioneering Prevention for A longer healthspan Reduced chronic
disease burden  A healthier future

Juvenescence is a clinical-stage drug development company dedicated to extending healthy lifespan through innovative medicines.

Our approach centres around developing medicines that target core pathways of aging to not only treat but prevent age-related diseases, ensuring that longevity comes with enhanced quality of life. 

By focusing on early disease intervention and prevention, we are committed to transforming how we age, ensuring that added years are healthy and fulfilling.

Multiple Clinical
Medicines from 2024

On track to have five medicines in Phase I or II trials by 2025. These therapies target aging mechanisms, offering early disease intervention.

Innovating across
modalities

Our expert team develops treatments using small molecules, biologics, and cell therapies, focusing on aging’s core pathways to impact various age-related conditions.

Longevity at the core

Our primary goal is prevention, with the notable advantage of potentially increasing lifespan by addressing fundamental aging processes.

OUR TEAM

World-class R&D Leadership

Powered by an unrivaled drug development team, we leverage cutting-edge data science approaches to unlock successful drugs in the aging and longevity space. Our team brings together over 150 years of combined pharmaceutical R&D experience and boasts multiple drug approvals.

Our leadership has an unrivalled track record for delivering value.
Meet Our Team

OUR TEAM

World-class R&D Leadership

Powered by an unrivaled drug development team, we leverage cutting-edge data science approaches to unlock successful drugs in the aging and longevity space. Our team brings together over 150 years of combined pharmaceutical R&D experience and boasts multiple drug approvals.

Our leadership has an unrivalled track record for delivering value.
Meet Our Team

OUR PIPELINE

Advancing Breakthrough Therapies

Our Pipeline

IN THE NEWS

Our latest developments

Incredible week at Abu Dhabi Global Health Week

April 18, 2025 Juv on the Road

M42 Announces Strategic Investment and Partnership with Leading Biotech Juvenescence

April 16, 2025 Press Releases

Relation Therapeutics announces two strategic collaborations with GSK to the tune of $300m

April 16, 2025 In the News

Incredible week at Abu Dhabi Global Health Week

Packed with bold ideas, global collaboration, and a shared vision for a future built on preventative, personalised healthcare.

M42 Announces Strategic Investment and Partnership with Leading Biotech Juvenescence

M42 announces a strategic investment and partnership with Juvenescence, a leading biotech company focused on extending human healthspan. This collaboration aims to develop cutting-edge therapies and advance research in longevity and age-related diseases.

Relation Therapeutics announces two strategic collaborations with GSK to the tune of $300m

Congratulations to the Relation team for securing this landmark partnership deal with GSK to advance therapeutics for fibrotic diseases and osteoarthritis. We're delighted and proud to be a founder investor in this great company.

Chrysea Unveils Groundbreaking Findings on Spermidine Dietary Intake and Cardiovascular Health at American Physiological Society (APS) Summit.

Extensive scientific research has long established the critical role of spermidine in activating autophagy, a vital cellular process that removes damaged cells and declines with age.

Relation Therapeutics secures $35 million of new seed financing led by DCVC and co-lead NVentures, NVIDIA’s venture arm

Relation Therapeutics, a biotechnology company, today announced $35 million in new seed financing, bringing its total seed fundraise to $60 million.

Data and Safety Monitoring Board Approves LyGenesis’s Phase 2a Clinical Trial to Continue and Dose Escalate in Novel Trial of Organ Regeneration

The next four patients will receive a higher dose of LyGenesis's cell therapy to grow functioning liver tissue in patients with end stage liver disease.

Hevolution Foundation

Our co-founder Dr. Greg Bailey took to the stage in Riyadh at Hevolution Foundation hashtag#GHS2025 with fellow investment leaders.

WHX Dubai

Reflecting on an inspiring & productive week at WHX Dubai - with the latest & best in healthcare innovation.

Buck Institute for Research on Aging

This week, four members of the Juvenescence® team—Kersten Small, Jeff Madwed, Steve Felstead, and myself—had the privilege of visiting the Buck Institute for Research on Aging.

Morphoceuticals

Listen in to Prof Michael Levin & Prof David Kaplan discussing the Morphoceuticals vision and groundbreaking approach of mapping & manipulating the bioelectrome to induce regeneration.

The Longevity Forum

Bridging science and society to help achieve longer, healthier and more fulfilled lives for as many people as possible.

Biomarkers of Aging Consortium

 I had the best time attending the 2024 Biomarkers of Aging Consortium Conference at Harvard Medical School !
1-800-555-7474
Contact Us